PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>Tirzepatide>>research-evidence
Approved medicine

Tirzepatide Research Evidence: Program Map

The key trials by name and what each established — the fastest way to navigate tirzepatide’s literature.

SURPASS program

The type 2 diabetes registrational series (SURPASS 1–5): HbA1c and weight efficacy, head-to-head comparisons against semaglutide 1 mg, dulaglutide, and degludec, and a CV-risk population study (SURPASS-CVOT ongoing).

SURMOUNT program

The obesity series: SURMOUNT-1 (−20.9% at 15 mg over 72 weeks), SURMOUNT-2 (T2D population), SURMOUNT-3/4 (intensive lifestyle and maintenance), SURMOUNT-5 (head-to-head versus semaglutide 2.4 mg, favoring tirzepatide on weight), SURMOUNT-OSA (sleep apnea).

Mechanism literature

Debate continues on how much of tirzepatide’s advantage over selective GLP-1 agents is attributable to GIP receptor activity versus pharmacokinetics — a genuine open scientific question this catalog tracks.

What is being studied now

Ongoing areas include cardiovascular outcomes, heart failure, MASH, and combination regimens with amylin analogs.

Educational content only — not medical advice. Dosing and treatment decisions belong with the approved label and a prescriber.

References

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. [source]
  2. ClinicalTrials.gov — registered tirzepatide studies. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement